These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32978942)

  • 61. Effectiveness of palivizumab prophylaxis in infants and children in Florida.
    Winterstein AG; Hampp C; Saidi A
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):53-60. PubMed ID: 21919115
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
    Simoes EA; Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study.
    Yi H; Lanctôt KL; Bont L; Bloemers BL; Weijerman M; Broers C; Li A; Kiss A; Mitchell I; Paes B;
    Pediatrics; 2014 Jun; 133(6):1031-7. PubMed ID: 24799541
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics.
    Krilov LR; Anderson EJ
    J Perinatol; 2020 Aug; 40(8):1135-1144. PubMed ID: 32499597
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A post-incorporation study on the use of palivizumab in the Brazilian public health system.
    Batista JDL; Ferreira MAP; Xavier CDS; Souza ITA; Cruz LN; Polanczyk CA
    Rev Inst Med Trop Sao Paulo; 2021; 63():e5. PubMed ID: 33533808
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland.
    Groves HE; Jenkins L; Macfarlane M; Reid A; Lynn F; Shields MD
    Pediatr Pulmonol; 2016 Apr; 51(4):379-85. PubMed ID: 26808981
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effectiveness of palivizumab in children with childhood interstitial lung disease: The French experience.
    Drummond D; Thumerelle C; Reix P; Fayon M; Epaud R; Clement A; Mahloul M; Habouria D; Delacourt C; Hadchouel A
    Pediatr Pulmonol; 2016 Jul; 51(7):688-95. PubMed ID: 26636747
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus.
    Blake SM; Tanaka D; Bendz LM; Staebler S; Brandon D
    Adv Neonatal Care; 2017 Aug; 17(4):292-298. PubMed ID: 27926583
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
    Resch B
    Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Respiratory syncytial virus reinfections among infants and young children in the United States, 2011-2019.
    Nduaguba SO; Tran PT; Choi Y; Winterstein AG
    PLoS One; 2023; 18(2):e0281555. PubMed ID: 36795639
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Full compliance with Respiratory syncytial virus prophylaxis was associated with fewer respiratory-related hospital admissions in preterm children: A cohort study.
    Torchin H; Charkaluk ML; Rousseau J; Marchand-Martin L; Treluyer L; Nuytten A; Truffert P; Jarreau PH; Ancel PY
    Acta Paediatr; 2021 May; 110(5):1633-1638. PubMed ID: 33249609
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
    Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
    Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
    Priante E; Tavella E; Girardi E; Militello MA; Mardegan V; Maule MM; Dall'Agnola A; Baraldi E; Manzoni P
    Am J Perinatol; 2019 Jul; 36(S 02):S77-S82. PubMed ID: 31238365
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prevalence and clinical characteristics of perinatal chronic lung disease by infant gestational age.
    Mavunda K; Jiang X; Ambrose CS
    J Neonatal Perinatal Med; 2021; 14(1):43-51. PubMed ID: 32474477
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Respiratory Syncytial Virus Infection-associated Hospitalization Rates in Infants and Children With Cystic Fibrosis.
    Metz J; Eber E; Resch B
    Pediatr Infect Dis J; 2017 Jun; 36(6):545-548. PubMed ID: 28005688
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
    Groothuis JR; Hoopes JM; Hemming VG
    Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.